Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has shared an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced that its board of directors will meet on August 29, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the declaration of an interim dividend and address other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its financial performance and investor relations.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$3.88 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the production and distribution of heparin products. The company operates in the pharmaceutical industry and focuses on providing high-quality heparin and related products to its market.
Average Trading Volume: 4,129,679
Technical Sentiment Signal: Buy
Current Market Cap: HK$19.38B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.